{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:17:04Z","timestamp":1776093424784,"version":"3.50.1"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Currently available echinocandins are generally effective against\n            <jats:named-content content-type=\"genus-species\">Candida<\/jats:named-content>\n            biofilms, but the recent emergence of resistance has underscored the importance of developing new antifungal agents that are effective against biofilms. CD101 is a long-acting novel echinocandin with distinctive pharmacokinetic properties and improved stability and safety relative to other drugs in the same class. CD101 is currently being evaluated as a once-weekly intravenous (i.v.) infusion for the treatment of candidemia and invasive candidiasis. In this study, we determined (i) the effect of CD101 against early and mature phase biofilms formed by\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            <jats:italic>in vitro<\/jats:italic>\n            and (ii) the temporal effect of CD101 on the formation of biofilms using time-lapse microscopy (TLM). Early- or mature-phase biofilms were formed on silicone elastomer discs and were exposed to the test compounds for 24 h and quantified by measuring their metabolic activity. Separate batches were observed under a confocal microscope or used to capture TLM images from 0 to 16 h. Measurements of their metabolic activity showed that CD101 (0.25 or 1 \u03bcg\/ml) significantly prevented adhesion-phase cells from developing into mature biofilms (\n            <jats:italic>P<\/jats:italic>\n            = 0.0062 or 0.0064, respectively) and eradicated preformed mature biofilms (\n            <jats:italic>P<\/jats:italic>\n            = 0.04 or 0.01, respectively) compared to those of untreated controls. Confocal microscopy showed significant reductions in biofilm thicknesses for both early and mature phases (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). TLM showed that CD101 stopped the growth of adhesion- and early-phase biofilms within minutes. CD101-treated hyphae failed to grow into mature biofilms. These results suggest that CD101 may be effective in the prevention and treatment of biofilm-associated nosocomial infections.\n          <\/jats:p>","DOI":"10.1128\/aac.01750-17","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T16:49:56Z","timestamp":1510591796000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms"],"prefix":"10.1128","volume":"62","author":[{"given":"Jyotsna","family":"Chandra","sequence":"first","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud A.","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03917.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.183.18.5385-5394.2001"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2008.192"},{"key":"e_1_3_3_5_2","first-page":"46","article-title":"Recurring and antimicrobial-resistant infections: considering the potential role of biofilms in clinical practice","volume":"53","author":"Saye DE","year":"2007","unstructured":"Saye DE. 2007. Recurring and antimicrobial-resistant infections: considering the potential role of biofilms in clinical practice. Ostomy Wound Manage 53:46\u201348, 50, 52 passim.","journal-title":"Ostomy Wound Manage"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0702.010226"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(02)00002-1"},{"key":"e_1_3_3_8_2","first-page":"186","article-title":"Candida biofilms: antifungal resistance and emerging therapeutic options","volume":"5","author":"Kuhn DM","year":"2004","unstructured":"Kuhn DM, Ghannoum MA. 2004. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 5:186\u2013197.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02396-16"},{"key":"e_1_3_3_10_2","first-page":"242","article-title":"Voriconazole \u2013 better chances for patients with invasive mycoses","volume":"7","author":"Ghannoum MA","year":"2002","unstructured":"Ghannoum MA, Kuhn DM. 2002. Voriconazole \u2013 better chances for patients with invasive mycoses. Eur J Med Res 7:242\u2013256.","journal-title":"Eur J Med Res"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1773-1780.2002"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.8.4333-4340.2003"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit136"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2096-9"},{"key":"e_1_3_3_15_2","unstructured":"Cidara Therapeutics Inc. 2017. CD101 compared to caspofungin followed by oral step down in subjects with candidemia and\/or invasive candidiasis (STRIVE). Clinical trial no. NCT02734862."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02045-16"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.03.028"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_3_3_20_2","volume-title":"Intersci Conf Antimicrob Agents Chemother (ICAAC) and Int Congr Chemother (ICC) joint meeting","author":"Ong V","year":"2015","unstructured":"Ong V, Hough G, Schlosser M, Bartizal K, Balkovec J, James K, Krishnana R. 2015. Preclinical evaluation shows CD101, a novel echinocandin, is highly stable with no hepatotoxicity in rats, abstr A-015. Intersci Conf Antimicrob Agents Chemother (ICAAC) and Int Congr Chemother (ICC) joint meeting, San Diego, CA."},{"key":"e_1_3_3_21_2","volume-title":"Abstr Intersci Conf Antimicrob Agents Chemother (ICAAC) and Int Congr Chemother (ICC) joint meeting","author":"Ong V","year":"2015","unstructured":"Ong V, Miesel L, Bartizal K, Huang HH, Chien JC. 2015. Prolonged efficacy following one dose of a novel echinocandin, CD101, in a neutropenic mouse model of disseminated candidiasis. Abstr Intersci Conf Antimicrob Agents Chemother (ICAAC) and Int Congr Chemother (ICC) joint meeting, San Diego, CA."},{"key":"e_1_3_3_22_2","volume-title":"Abstr Intersci Conf Antimicrob Agents Chemother (ICAAC) and Int Congr Chemother (ICC) joint meeting","author":"Rubino CM","year":"2015","unstructured":"Rubino CM, Thye OVD, Ambrose PG. 2015. Pharmacokinetics-pharmacodynamics (PK-PD) of a novel echinocandin, CD101 (biafungin), in a neutropenic murine disseminated candidiasis model. Abstr Intersci Conf Antimicrob Agents Chemother (ICAAC) and Int Congr Chemother (ICC) joint meeting, San Diego, CA."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw162"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.01.007"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02290-12"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12640"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-17"},{"key":"e_1_3_3_28_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother (ICAAC)","author":"Castanheira M","year":"2014","unstructured":"Castanheira M, Messer SA, Rhomberg PR, Jones RN, Pfaller MA. 2014. Activity of a novel echinocandin biafungin (CD101) tested against most common Candida and Aspergillus species, including echinocandin- and azole-resistant strains. Abstr 54th Intersci Conf Antimicrob Agents Chemother (ICAAC), Washington, DC."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw214"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00620-16"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","unstructured":"Lepak AJ VanScoy MZB Ambrose PG Andes DR. 2017. In vivo pharmacokinetic\/pharmacodynamic (PK\/PD) target characterization of the novel long-acting echinocandin CD101 against C. albicans and C. glabrata in the neutropenic murine disseminated candidiasis model poster 1528. IDweek San Diego CA 4 to 8 October 2017.","DOI":"10.1093\/ofid\/ofx163.1224"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12780"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.11.19"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02378-12"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/651200"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01750-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01750-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:13:59Z","timestamp":1645478039000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01750-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1128\/AAC.01750-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01750-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"2017-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01750-17"}}